Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Refine the approach

Untreated patient

THE KALLIKREIN-KININ PATHWAY IN HAE11

HAE ATTACK FXII HMWK PLASMA KALLIKREIN PLASMA KALLIKREIN PRE- KALLIKREIN HMWK HMWK cHMWK Bradykinin cHMWK FXIIa C1-INH Positive feedback loop

When C1-INH is deficient or dysfunctional, plasma kallikrein activity is increased.1

This leads directly to excessive bradykinin production and, ultimately, HAE attacks1

cHMWK=cleaved high molecular weight kininogen, FXII=factor XII; FXIIa=factor XIIa; HMWK=high molecular weight kininogen.

Patient treated with TAKHZYRO

FXII HMWK PLASMA KALLIKREIN PLASMA KALLIKREIN PRE- KALLIKREIN HMWK HMWK TAKHZYRO FXIIa C1-INH Positive feedback loop Prevention of attacks

The first and only mAb for HAE1-4

TAKHZYRO provides targeted inhibition of plasma kallikrein, a critical regulator of bradykinin production, to help prevent HAE attacks.1

Direct inhibition of plasma kallikrein controls excess bradykinin production.1

For patients aged 12 and older, just 1 subcutaneous injection, every 2 weeks1*

*The recommended starting dose for adults and adolescents is 300 mg every 2 weeks. TAKHZYRO every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1

Review Dosing Information

See efficacy and safety data across all 3 studies

Explore the results of the HELP study, the HELP open-label extension study, and the SPRING study.

Explore the Data

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2022. 2. Cinryze. Prescribing information. Takeda Pharmaceuticals; 2021. 3. Haegarda. Prescribing information. CSL Behring LLC; 2020. 4. Orladeyo. Prescribing information. BioCryst Pharmaceuticals, Inc; 2020.